 |
인쇄하기
취소
|
Iressa shows promise in advanced NSCLC
Follow-up study results show that Iressa (gefinitib) is effective in the treatment of advanced non-small cell lung cancer (NSCLC) in Korean patients, according to the Korean Cancer Study Group.
Prof. Kang Jin-hyung of Kangnam St. Mary hospital said that at least 50 percent of reduction in tumor size occurred in 20.5 percent of 610 NSCLC patients receiving 250 mg daily in a following-up study...
Prof. Kang Jin-hyung of Kangnam St. Mary hospital said that at least 50 percent of reduction in tumor size occurred in 20.5 percent of 610 NSCLC patients receiving 250 mg daily in a following-up study...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.